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a b s t r a c t
LncRNAs appear to play a considerable role in tumourigenesis through regulating key processes in cancer
cells such as proliferative signalling, replicative immortality, invasion and metastasis, evasion of growth
suppressors, induction of angiogenesis and resistance to apoptosis. LncRNAs have been reported to play a
role in prostate cancer, particularly in regulating the androgen receptor signalling pathway. In this review
article, we summarise the role of 34 lncRNAs in prostate cancer with a particular focus on their role in the
androgen receptor signalling pathway and the epithelial to mesenchymal transition pathway.
© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
1. Introduction
Prostate cancer (PCa) is one of the most common forms of
cancer and is the third leading cause of cancer-related deaths in
men in the USA [1]. PCa is usually hormone-dependent at diagnosis
highlighting the importance of androgen signalling in this disease.
While the majority of patients with PCa are treated successfully
with surgery and/or radiotherapy, metastatic disease develops in a
significant proportion of patients. Androgen deprivation therapy
(ADT) is initially effective in these patients but, invariably, resis-
tance emerges. This form of PCa, known as castration resistant PCa
(CRPC), is currently incurable.
Sustained androgen receptor (AR) signalling is a key feature of
CRPC [2]. The AR is a ligand-activated transcription factor normally
responsive to the androgens testosterone and dihydrotestosterone.
However, CRPC progresses despite low/absent levels of circulating
androgens. Mechanisms for sustained AR signalling despite low
levels of circulating androgens include AR overexpression, aberrant
activation of AR transcription and the development of AR variants
[3,4].
It has now become apparent that the vast majority of human
RNA transcripts are non-coding. Approximately 70e90% of the
human genome is transcribed into RNA but only roughly 2% of the
genome encodes for protein [5]. This large group of non-coding
RNAs are broadly divided into two categories: small non-coding
RNAs, <200 nucleotides long, and long non-coding RNAs
(lncRNAs), >200 nucleotides long. While much work has focused
on the function of small non-coding RNAs, we are only beginning to
understand the role of lncRNAs in the regulation of gene
expression.
Over 100,000 lncRNAs have been identified in the human
genome to date [6]. They exhibit both nuclear and cytoplasmic
localisation and are involved in the regulation of key cellular pro-
cesses including transcription, translation, cell cycle regulation,
cellular differentiation and nuclear-cytoplasmic trafficking [7,8].
The mechanisms through which this regulation is achieved are
incompletely understood but include transcriptional interference,
recruitment of chromatin remodelling complexes to specific gene
loci, and by acting as competing endogenous RNAs [9].
This suggests a wide-ranging role for lncRNAs in gene
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regulation, so it is unsurprising that aberrant expression of lncRNAs
appear to play a considerable role in human tumourigenesis [10,11].
LncRNAs appear to regulate key functions in cancer cells including
sustained proliferative signalling, replicative immortality, invasion
and metastasis, evasion of growth suppressors, induction of
angiogenesis and resistance to apoptosis [12].
Although numerous lncRNAs have been implicated in prostate
carcinogenesis [13], in many incidences, their functional role re-
mains unknown or partially understood. The aim of this review is to
collate the information in the literature related to lncRNAs in PCa,
present a short summary on the most relevant lncRNAs and then
discuss how these lncRNAs affect critical pathways in PCa
pathogenesis.
2. LncRNAs associated with prostate cancer
2.1. CCAT2 (Colon Cancer-Associated Transcript 2)
The CCAT2 gene is located on chromosome 8q24, a known PCa
locus. A recent study [14] examined fresh tissue from 96 patients
with PCa and found that expression levels of CCAT2 were signifi-
cantly higher in PCa tissues compared to adjacent non-tumour
tissue. Upregulation of CCAT2 was positively associated with the
histological grade and tumour stage, and Kaplan-Meier survival
analysis revealed that patients with high CCAT2 expression levels
had poorer overall survival and progression-free survival than pa-
tients with low CCAT2 expression [14]. Multivariate analysis also
showed that the status of CCAT2 expression was an independent
prognostic indicator [14].
In vitro, expression levels of CCAT2 were also demonstrated to
be higher in PCa cell lines compared to a normal prostate stromal
cell line [14]. Knockdown of CCAT2 impaired cellular proliferation,
migration and invasion. Furthermore, it decreased expression of N-
cadherin and vimentin and increased expression of E-cadherin,
suggesting that CCAT2 may play a role in regulating EMT [14].
2.2. CTBP1-AS (C-Terminal Binding Protein 1 Antisense)
CTBP1-AS is located in the anti-sense region of CTBP1, a gene
that is reported to function as an AR corepressor [15]. In support of
this, lower CTBP1 expression is associatedwith poor cancer-specific
survival and PSA-free survival, and CTBP1 overexpression is asso-
ciated with reduced cell proliferation and repression of androgen-
regulated genes [15].
CTBP1-AS represses CTBP1 expression by interacting with PTB-
associated splicing factor (PSF), which binds at the CTBP1 pro-
moter to induce histone deacetylation [15]. CTBP1-AS promotes cell
cycle progression and tumour cell proliferation, is frequently
overexpressed in PCa and is significantly correlated with high
Gleason scores and overexpression of the AR. Expression levels of
CTBP1-AS increase during ADT. In addition, PSF and CTBP1-AS
promote cell cycle progression by repressing SMAD3 and p53,
two cell cycle inhibitors. CTBP1-AS also mimics AR signalling by
inducing upregulation of AR-regulated genes [15].
2.3. DANCR (Differentiation Antagonising Non-protein Coding RNA)
A single study reported that DANCR is upregulated in PCa and
elevated expression is associated with high-grade tumours [16]. It
promotes invasion and migration of prostate cancer cells in vitro
and represses TIMP2/3 expression by mediating the binding of
EZH2 on the TIMP2/3 promoter. TIMP2/3 has been reported to
prevent invasion and metastatic spread in PCa [17].
2.4. DRAIC (Downregulated RNA in Androgen Independent Cells)
A recent study reported that DRAIC exerts suppressive functions
by preventing themigration andmetastatic spread of PCa cells [18].
This study reported that low levels of DRAIC are associated with
increased rates of biochemical recurrence in patients with localised
PCa. The AR pathway represses the transcription of DRAIC while
FOXA1 and NKX3.1 induce the transcription of DRAIC. During the
progression from PCa to CRPC, the expression of FOXA1 and NKX3.1
decrease and the AR pathway is aberrantly activated resulting in
decreased levels of DRAIC.
2.5. FALEC (Focally Amplified LncRNA in Epithelial Cancer)
Zhao et al., reported that FALEC expression is significantly
increased in PCa tissue samples compared to adjacent normal tis-
sue [19]. This study reported that knockdown of FALEC inhibited
cell proliferation, migration and invasion in vitro. In addition, PCa
cells subjected to a hypoxic environment showed increased
expression of FALEC and HIF-1a. Knockdown of HIF1a caused a
reduction in FALEC expression whereas overexpression conferred
the opposite effect.
2.6. GAS5 (Growth Arrest Specific 5)
GAS5 is abundant in cells whose growth has arrested due to a
lack of nutrients or growth factors [20]. Suppression of mTOR ac-
tivity, such as occurs upon growth arrest, prevents degradation of
GAS5 transcripts by the nonsense mediated decay (NMD) pathway
leading to an accumulation of GAS5 transcripts [21]. GAS5 accu-
mulation results in increased susceptibility to apoptosis by inhib-
iting the anti-apoptotic action of glucocorticoids [22]. GAS5 binds
to the DNA-binding domain of the glucocorticoid receptor, thus
competing with DNA glucocorticoid response elements for binding.
Importantly, GAS5 can also sequester the androgen/AR complex
and prevent it binding to target DNA sequences [22].
In CRPC, GAS5 is downregulated and it has been shown to in-
crease apoptosis and decrease cell survival in vitro [23]. The use of
mTOR inhibitors leads to an increase in GAS5 levels in androgen-
dependent and androgen-sensitive PCa cell lines but not in
androgen-independent cell lines [24].
A further study [25] reported that GAS5 inactivates the PI3K-
AKT-mTOR signalling pathway in PCa by targeting miR-103. Over-
expression of GAS5 was shown to significantly decelerate PCa cell
progression in vitro and tumour growth in vivo through inactivating
the PI3K-AKT-mTOR signalling pathway.
In terms of cell cycle, GAS5 is also reported to induce the
expression of P27Kip1, which regulates the progression at the G1 to S
phase transition [26]. GAS5 interacts with E2F1, a transcription
factor, and enhances the binding of E2F1 to the P27Kip1 promoter.
2.7. HCG11 (HLA Complex Group 11)
HCG11 is an androgen-responsive lncRNA, downregulation of
which is associated with a poor prognosis in PCa [27]. This study
reported that expression of HCG11 was significantly lower in PCa
tissue compared to non-tumour tissue.
2.8. HOTAIR (HOX Transcript Antisense RNA)
Zhang et al. reported that HOTAIR is repressed by androgens and
is therefore upregulated in CRPC [28]. The study demonstrated that
HOTAIR binds to the N-terminal domain of the AR, blocking the
binding of E3 ubiquitin ligase MDM2 which interacts with the AR
through the same domain. This prevents AR ubiquitination and
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degradation, and leads to increased AR gene expression. They also
reported that HOTAIR overexpression can induce an AR-binding
profile similar to that induced by androgens resulting in activa-
tion of the AR transcriptional programme in the absence of an-
drogens. HOTAIR overexpression was found to increase PCa cell
growth in vitro with knockdown of HOTAIR having the opposite
effect. Levels of HOTAIR were also found to increase in LNCaP cell
lines upon treatment with enzalutamide [28].
Another study reported that an increase in infiltrating mast cells
enhanced PCa invasion via modulation of the interaction between
HOTAIR and Polycomb Repressive Complex 2 (PRC2) [29]. PCa cells
treated with ADT using casodex or enzalutamide were reported to
recruit more mast cells.
Genistein, a soy isoflavone, has been reported to inhibit PCa cell
growth in AR-negative cell lines through downregulation of
HOTAIR [30]. This study also reported that HOTAIR is targeted by
miR-34a and that knockdown of HOTAIR decreased PCa cell pro-
liferation, migration and invasion and induced apoptosis and cell
cycle arrest.
2.9. LINC01296 (Long Intergenic Non-protein-coding RNA 1296)
A single study reported that LINC01296 expression promotes
PCa growth and metastasis by activating the PI3K-AKT-mTOR sig-
nalling pathway and promoting EMT [31]. Patients with higher
LINC01296 expression displayed advanced clinical features and
shorter biochemical recurrence-free survival time than those with
lower LINC01296 expression. LINC01296 expression correlated
with preoperative PSA level, lymph node metastasis, Gleason score
and tumour stage. Multivariate analysis showed that LINC01296
expression was an independent predictor of biochemical
recurrence-free survival.
2.10. LincRNA-p21 (Long Intragenic Non-coding RNA p21)
A single study reported that LincRNA-p21 suppresses the
development of PCa [32]. LincRNA-p21 expression inhibited PCa
cell proliferation and colony formation in vitro and reduced the rate
of PCa cell population growth in vivo. It promoted apoptosis and
induced expression of p53 responsive genes by regulating p53
binding to their promoters. In malignant prostate tissue, the
expression of p53 downstream genes such as MDM2, Puma, Noxa
and Bax, were reduced and correlated with reduced expression of
lincRNA-p21. Low levels of LincRNA-p21 correlated with higher
disease stage and predicted poor overall and disease-free survival.
2.11. LncRNA-ATB (Long non-coding RNA-activated by transforming
growth factor b)
A single study reported that LncRNA-ATB expression was
significantly upregulated in PCa tumour tissue compared to adja-
cent non-tumour tissue [33]. High levels of lncRNA-ATB correlated
with high preoperative PSA level, pathological stage, high Gleason
score, lymph node metastasis, angiolymphatic invasion and
biochemical recurrence. LncRNA-ATB expression increased cell
proliferation and increased expression levels of the cell cycle reg-
ulatory proteins cyclin E and cyclin D1 in vitro.
Knockdown of lncRNA-ATB increased expression levels of E-
cadherin and ZO-1 and decreased expression levels of N-cadherin
and Vimentin in vitrowhile overexpression had the opposite effect,
suggesting a role in EMT. Upregulation of lncRNA-ATB also led to
upregulation of ZEB1 and ZNF217, and to activation of the PI3K-
AKT-mTOR and ERK signalling pathways, all of which have been
implicated in EMT [33].
2.12. LOC283070
A single study reported that LOC283070 plays an important role
in the transition of LNCaP cells from an androgen-dependent state
to an androgen-independent state [34]. Overexpression of
LOC283070 in LNCaP cells accelerated cell proliferation and
migration in both androgen dependent and independent LNCaP cell
lines. Overexpression of LOC283070 also promoted tumour growth
in vivo in both normal and castrated mice. Overexpression of
CAMK1D had similar effects to LOC283070 on the transition of
LNCaP cells to an androgen-independent statewhile its knockdown
fully abrogated the effect of LOC283070 overexpression suggesting
a relationship between CAMK1D and LOC283070.
2.13. LOC400891
A single study reported that LOC400891 was significantly
upregulated in PCa tissue compared to adjacent non-tumour tissue
[35]. LOC400891 was also overexpressed in DU-145 and 22RV1 PCa
cell lines compared to the normal human stromal cell line, WPMY-
1. Patients with high LOC400891 expression had a significantly
shorter biochemical recurrence-free survival time than those with
low LOC400891 expression. In vitro experiments suggested that
LOC400891 is involved in the promotion of PCa cell proliferation
and metastasis and this may be mediated by modulation of the
PI3K-AKT-mTOR pathway and PTEN gene. In addition, LOC400891
may function as an inducer of EMT.
2.14. LOC440040
A single study reported that LOC440040 was significantly
upregulated in PCa tissue compared to non-tumour tissue [36].
LOC440040 expression level was also significantly increased in PC3
and 22RV1 cell lines but not in the DU-145 cell line when compared
to the normal human stromal cell line, WPMY-1. Patients with high
expression levels of LOC440040 had a significantly shorter
biochemical recurrence-free survival time than those with low
expression levels. LOC440040 promoted the proliferation of PCa
cells in vitro, possibly mediated by the PI3K-AKT-mTOR pathway. In
addition, LOC440040 may be associated with EMT.
2.15. MALAT-1 (Metastasis Associated Lung Adenocarcinoma
Transcript 1)
Ren et al. reported that MALAT-1 is overexpressed in human PCa
tissues and cell lines [37]. High MALAT-1 expression levels corre-
lated with high Gleason score and tumour stage. Expression levels
increased during the progression from hormone-sensitive to
castration-resistant states. Suppression ofMALAT-1 in vitro resulted
in reduced cell growth, invasion, migration and colony formation,
and increased rates of apoptosis and cell cycle arrest. Suppressing
expression in vivo delayed tumour growth and reduced metastasis
of PCa xenografts in castrated nude mice.
Another study reported that MALAT-1 binds to EZH2, a core
subunit of PRC2 that is also frequently overexpressed in PCa,
especially CRPC [38]. MALAT-1 enhanced EZH2-mediated PCa cell
invasion and migration, and EZH2-mediated repression of PRC2-
dependent target genes such as DAB2IP and BRACHYURY. MALAT-
1 also enhanced the expression of EZH2 target genes that are in-
dependent of PRC2 such as CKS2 and TMEM48.
A recent study reported that MALAT-1 is required for enzalu-
tamide induced AR-V7 production and may enhance splicing of AR-
V7 through direct modulation of SF2 binding and activity [39].
MALAT-1 expression and SF2 activity were upregulated in enzalu-
tamide resistant PCa cell lines, contributed to AR-V7 production
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and led to drug resistance.
MALAT-1 has also been reported to promote bone metastasis in
PCa [40]. An in vitro co-culture model of PC3 cells and osteoblasts
was used to identify PCa-bone microenvironment interactions.
Factors secreted by PC3 cells resulted in the downregulation ofWnt
inhibitor, Sost, in osteoblasts suggesting that Sost may play a role in
facilitating PCa metastasis to bone. Downregulation of Sost led to a
significant upregulation of MALAT-1 in PC3 cells.
2.16. MEG3 (Maternally Expressed 3)
A single study showed expression levels of MEG3 were signifi-
cantly lower in PCa tissue compared to non-tumour tissue,
although no significant relationship betweenMEG3 expression and
clinical characteristics was identified [41]. MEG3 suppressed cell
proliferation and induced apoptosis in vitro. It increased the pro-
portion of cells in G0/G1 phase and decreased the proportion of
cells in S phase. It induced Bax protein expression and activated
caspase-3, both of which are associated with pro-apoptotic activity,
and inhibited Bcl-2 and Cyclin D1 protein expression.
MEG3 has also been reported to act as a tumour suppressor by
activating p53, causing impaired cell proliferation and promotion of
apoptosis [42].
2.17. NEAT1 (Nuclear Enriched Abundant Transcript 1)
Oestrogen receptor alpha (ERa) is expressed in PCa and may
comprise an important AR-independent mechanism of signalling in
CRPC [43]. ERa regulates the expression of TMPRSS2-ERG fusion
gene and induces the transcription of NEAT1. A single study re-
ported that NEAT1 and ERa levels are significantly higher in CRPC
compared to PCa, and that NEAT1 levels increase upon treatment
with tamoxifen, bicalutamide or enzalutamide [43]. NEAT1 pro-
moted cellular proliferation and invasion both in vitro and in vivo,
and NEAT1 levels were positively associated with biochemical
recurrence and metastasis. PCa cells expressing high levels of
NEAT1 were resistant to ADT or AR antagonists.
2.18. PCA3 (Prostate Cancer Antigen 3)
PCA3 expression is highly specific for PCa and therefore has
been used as a clinical biomarker [44]. PCA3 appears to be involved
in EMT, as knockdown of PCA3 leads to upregulation of epithelial
markers E-cadherin, claudin-3 and CK18 and downregulation of
vimentin [45]. PCA3 knockdown also inhibited AR signalling, cell
growth and viability [45]. It has been reported to regulate the
expression of genes involved in angiogenesis, signal transduction
and apoptosis and to regulate the tumour suppressor, PRUNE2 [46].
The transcription factor Snail is reported to activate the
expression of PCA3 by binding to its promoter region [47]. PCA3, in
turn, negatively regulates the expression of miR-1261 through
competitive sponging [47]. PRKD3 is negatively regulated by miR-
1261 meaning that increased PCA3 can result in high expression
of PRKD3, which can promote invasion and metastasis of PCa.
Another study reported that PCA3 knockdown reduced the
expression of AR-related genes PSA and PCGEM1, and sensitised
PCa cells to enzalutamide-induced loss of cell growth [48].
2.19. PCAT1 (Prostate Cancer Associated Transcript 1)
Double-stranded DNA breaks (DSBs) are repaired by several
mechanisms including homologous recombination (HR) [49].
BRCA1/2 mutations lead to defective HR and increased DSBs [49].
PCAT1 expression has been reported to cause repression of BRCA2
which leads to an impairment in HR which, in turn, imparts a high
sensitivity to PARP1 inhibitors [50].
PCAT1 has also been reported to increase cell proliferation by
enhancing the expression of cMyc protein [51]. PCAT1 post-
transcriptionally upregulates cMyc and interferes with the down-
regulation of MYC by miR-34a. Conversely, targeting of PCAT1 by
another microRNA, miR-3667-3p, reverses its effect on cMyc [51]. A
further study reported that PCAT1 upregulates FSCN1 by acting as a
miR-145-5p sponge resulting in increased PCa cell proliferation,
migration, invasion and suppressed apoptosis [52].
2.20. PCAT5 (Prostate Cancer Associated Transcript 5)
A single study reported that knockdown of PCAT5 resulted in
enhanced apoptosis and reduced cell proliferation and invasion of
PCa cells in vitro [53]. PCAT5 was reported to be exclusively over-
expressed in ERG-positive PCa and CRPC tissue compared to non-
tumour prostate tissue. Knockdown of ERG resulted in a reduc-
tion of PCAT5 levels.
2.21. PCAT14 (Prostate Cancer Associated Transcript 14)
A study reported that PCAT14 is regulated by the AR and over-
expression of PCAT14 suppresses the invasive capabilities of PCa
cells [54]. PCAT14 expression was associated with favourable out-
comes in biochemical progression-free survival, metastasis-free
survival and PCa-specific survival. Another study analysed radical
prostatectomy microarray and clinical data from 910 patients and
found PCAT14 to be the most prevalent aberrantly expressed
lncRNA [55]. Lower PCAT14 expression was significantly associated
with unfavourable outcomes in distant metastasis-free survival,
PCa specific survival and overall survival.
2.22. PCAT18 (Prostate Cancer Associated Transcript 18)
A single study reported PCAT18 was upregulated in PCa tissue
compared to non-tumour tissue and was highly expressed in CRPC
[56]. AR activation dramatically upregulated PCAT18 expression
in vitro and in vivo, and knockdown of PCAT18 significantly
inhibited PCa cell proliferation, migration and invasion.
2.23. PCAT29 (Prostate Cancer Associated Transcript 29)
It has been reported that PCAT29 functions as a tumour sup-
pressor and is repressed by androgen signalling [57]. AR binds to
the PCAT29 promoter and suppresses its transcription [57]. In this
study [57], knockdown of PCAT29 increased cell proliferation and
the migration of PCa cells in vitro whereas overexpression
conferred the opposite effect. In patient specimens, low PCAT29
expression correlated with significantly higher rates of biochemical
recurrence.
Another study [58] reported IL-6, a cytokine which is elevated in
prostate tumours [59], reduced the expression of PCAT29 in both
DU145 and LNCaP cell lines. IL-6 activates STAT3 which induces
miR-21. This interaction leads to the repression of PCAT29. Inhibi-
tion of miR-21 was shown to increase PCAT29 expression [58].
2.24. PCGEM1 (Prostate Cancer Gene Expression Marker 1)
Yang et al. reported that PCGEM1 activates the AR in vitro and
that PCGEM1 acts in association with PRNCR1 to physically bind to
the AR [60]. Both PCGEM1 and PRNCR1 were highly upregulated in
CRPC cell line models and were reported to activate the AR in the
absence of androgen.
However, these findings were disputed by Prensner et al., who
reported that PCGEM1 and PRNCR1 were not implicated in CRPC or
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AR signalling [61]. A further study by Parolia et al. reported that
PCGEM1 was highly expressed in PCa while PRNCR1 showed scant
expression. PCGEM1 was implicated in early stage PCa but not in
metastatic PCa, was significantly downregulated in metastatic tu-
mours relative to primary tumours, and significantly repressed in
patients exhibiting poor clinical outcomes [62]. They also reported
that in vivo stimulation of the AR led to upregulation of PCGEM1
(Refer to section 3.1.1).
Zhang et al. reported that ADT induced PCGEM1 and that this
expression was associated with the expression of AR-V7 [63]. ADT
led to an upregulation of PCGEM1, which relocated to the nucleus,
and enhanced interaction with the splicing factors U2AF65 and
hnRNP A1. The interaction with U2AF65, an enhancer of AR-V7, led
to increased activity of the splicing factor to AR pre-mRNA. Inter-
action with hnRNP A1, a negative regulator of AR-V7, reduced the
affinity of hnRNP A1 to AR pre-mRNA.
Another study by Ho et al. reported that PCGEM1 is regulated by
p54/nrb, a multifunctional nuclear protein involved in a variety of
nuclear processes [64]. PCGEM1 was upregulated through the ac-
tion of p54/nrb in response to androgen deprivation which also led
to upregulation of AR-V7.
Hung et al. reported that PCGEM1 regulates tumour metabolism
by enhancing activation of cMyc and the AR [65]. PCGEM1 directly
bound cMyc and facilitated the recruitment of cMyc to target sites.
A further study reported that downregulation of PCGEM1
increased the expression of miR-145, a miRNA that appears to
function as a tumour suppressor [66]. In addition, overexpression of
miR-145 decreased PCGEM1 expression as well as inhibiting cell
proliferation, migration and invasion, and also induced early
apoptosis. It was suggested that miR-145 may regulate PCGEM1
expression by directly binding to target sites within the PCGEM1
sequence.
2.25. PlncRNA-1
A study reported that PlncRNA-1 is overexpressed in PCa and
knockdown of PlncRNA-1 leads to enhanced apoptosis and reduced
cell proliferation [67]. Knockdown also led to decreased expression
of AR and NKX3-1, a downstream target of AR. Knockdown of AR
caused decreased levels of PlncRNA-1.
PlncRNA-1 appears to protect the AR from miRNA-mediated
suppression [68]. Experiments showed that PlncRNA-1 acts as a
sponge for certain AR targeting miRNAs such as miR-34c and miR-
297.
PlncRNA-1 is also reported to regulate both the cell cycle and
EMT through the TGF-b1 pathway [69], and to regulate CyclinD1
levels through the Her-2 pathway [70]. Downregulation of
PlncRNA-1 was associated with a decrease in Her-2 protein
expression and an increase in apoptosis.
2.26. POTEF-AS1 (Prostate Ovary Testis Expressed Family member
Antisense 1)
A single study reported that the expression of POTEF-AS1 was
regulated by the AR in vitro [71]. It promoted cell growth, inhibited
apoptosis and repressed genes related to the Toll-like receptor
signalling pathway including TLR3, CXCL10 and TNFSF10.
2.27. PRNCR1 (Prostate Cancer Associated Non-coding RNA 1)
A study reported that PRNCR1 expression was upregulated in
PCa cells and knockdown of PRNCR1 reduced the viability of PCa
cells and the activity of the AR [72]. PRNCR1 was also reported to
associate with PCGEM1 and physically bind to the AR [60]. How-
ever, this result has been disputed and as two studies have failed to
show upregulation of PRNCR1 in PCa [61,62] (Refer to Section 2.24).
2.28. PVT1 (Plasmacytoma Variant Translocation 1)
PVT1 is overexpressed in PCa and is reported to be involved in
the regulation of tumour growth [73,74]. PVT1 can regulate PCa cell
viability and apoptosis in associationwith miR-146a [75]. MiR-146a
was downregulated and negatively correlated with PVT1 levels in
PCa. PVT1 regulated miR-146a expression by inducing the
methylation of CpG Island in its promoter. Another study reported
that PVT1 knockdown significantly upregulated the expression of
cleaved caspase-3 and cleaved caspase-9 and downregulated the
expression of cMyc in PCa [74].
2.29. SChLAP1 (Second Chromosome Locus Associated with Prostate
1)
Multiple studies have reported that SChLAP1 is overexpressed in
PCa, especially CRPC, and is predictive for poor patient outcomes
[76e79]. It interacts with the SWI/SNF complex, impairing its
ability to regulate gene expression, resulting in the promotion of
cell invasion and metastasis [78]. SChLAP1 appears to counteract
the tumour-suppressive effects of the SWI/SNF complex by directly
disrupting SNF5, a core subunit of the SWI/SNF complex [80]. It has
also been reported that SChLAP1 acts via targeting miR-198 and
promoting the MAPK1 pathway [81]. SChLAP1 acts as a negative
regulator of miR-198.
2.30. SNHG1 (Small Nucleolar RNA Host Gene 1)
A single study reported that SNHG1 was upregulated in PCa and
negatively regulates miR-199a-3p by acting as a competing
endogenous RNA [82]. This resulted in enhanced CDK7 expression
and promotion of PCa cell proliferation and cell cycle progression.
2.31. SOCS2-AS1 (Suppressor of cytokine signalling 2 antisense)
A single study reported that SOCS2-AS1, an androgen-induced
lncRNA, promoted castration resistant and androgen-dependent
cell growth, and enhanced the migration potential of PCa cells
in vitro [83]. The authors reported that SOCS2-AS1 regulates genes
involved in cellular proliferation, apoptosis and the cell cycle such
as TNFSF10, FOXM1 and CENPF. They also suggested that high AR
signalling in CRPC may lead to overexpression of SOCS-AS1.
2.32. TRPM2-AS (Transient Receptor Potential Cation Channel
Subfamily M Member 2 Antisense)
A single study reported that TRPM2-AS is overexpressed in PCa
and is associated with a poor prognosis [84]. As well as regulating
the TRPM2 gene, TRPM2-AS regulates the expression of a number
of genes involved in cell survival and the cell cycle such as the
oncogenes FYN and AKT1 [85].
2.33. UCA1 (Urothelial Cancer Associated 1)
Studies have reported that UCA1 is abnormally upregulated in
PCa tissue and is associated with poor clinical outcomes [86,87]. It
appears to regulate cell growth, migration and invasion, and inhibit
apoptosis [86,87]. It is also associated with drug resistance in
various cancers, including PCa [88]. In one study, expression levels
of KLF4 in PCa tissue correlated with UCA1 levels [86] and knock-
down of UCA1 decreased KLF4 expression. KLF4 plays a key role in
cancer cellular differentiation and proliferation [89]. Knockdown of
UCA1 also resulted in the downregulation of KRT6 and KRT13.
J. Aird et al. / Non-coding RNA Research 3 (2018) 29e38 33
UCA1 has been reported to act as a competitive endogenous
RNA and downregulates the expression of miR-204 [87]. In one
study, the authors reported that this resulted in upregulation of the
ATF2 gene as miR-204 causes the degradation of ATF2 [87]. Another
study reported that miR-204 negatively modulates Sirt1 expression
and that UCA1 overexpression results in increased Sirt1 expression
[90]. Upregulation of Sirt1 is associated with enhanced tumour cell
proliferation, invasion and migration and the promotion of EMT.
2.34. ZEB1-AS1 (Zinc Finger E-box Binding Protein 1)
ZEB1-AS1 has been reported to promote the proliferation and
migration of PCa cells and also promote ZEB1 expression by binding
and recruiting histone methyltransferase MLL1 to the promoter
region of ZEB1 [91]. ZEB1 promotes many tumour biological be-
haviours including EMT.
ZEB1-AS1 also indirectly regulates BMI1, a regulator of prostate
stem cells [92]. BMI1 is associated with metastatic disease and poor
clinical outcomes [93]. BMI1 is directly repressed by miR200c,
which is itself directly inhibited by ZEB1 and ZEB1-AS1 [91].
Therefore, upregulation of ZEB1-AS1 results in the upregulation of
BMI1 via the repression of miR-200c.
3. Involvement of lncRNAs in specific pathways in PCa
Certain pathways are important in the pathogenesis of PCa, the
most important of which is the pathway regulated by the AR. In
addition, the EMT pathway is an important pathway in the path-
ogenesis of metastatic PCa. Below, we summarise the roles of
lncRNAs currently identified as playing roles in these pathways.
3.1. Androgen/AR Pathway
3.1.1. Positive regulation of the AR
Upregulation of the AR is a feature of CRPC and may be one
mechanism facilitating AR signalling despite absent/low levels of
endogenous androgens. Certain lncRNAs (CTBP1-AS and HOTAIR)
are upregulated after ADT suggesting that they are negatively
regulated by androgens (Fig. 1). The upregulation of these lncRNAs
result in upregulation of the AR.
CTBP1-AS upregulation results in downregulation of CTBP1.
CTBP1 negatively regulates the AR by inhibiting androgen-
mediated demethylation [15]. Therefore, downregulation of
CTBP1 by CTBP1-AS results in upregulation of the AR (Fig. 1).
HOTAIR binds to the N-terminal domain of the AR (Fig. 1),
blocking the binding of E3 ubiquitin ligase MDM2, which interacts
with the AR through the same domain [28]. This prevents AR
ubiquitination and degradation. HOTAIR overexpression can also
induce an AR-binding profile similar to that induced by androgen
thus resulting in activation of the AR transcriptional programme in
the absence of androgen.
There are conflicting reports regarding PCGEM1 and whether it
is upregulated after ADT and if it interacts with the AR. Yang et al.
reported that PCGEM1 and PRNCR1 bind to the AR and enhance AR-
mediated gene activation programmes [60]. PCGEM1 was reported
to be dependent on PRNCR1 for binding. Both PCGEM1 and PRNCR1
were highly upregulated in CRPC cell line models and were re-
ported to activate the AR in the absence of androgen. Knockdown of
either PCGEM1 or PRNCR1 significantly inhibited in vivo tumour
growth in a xenograft mouse model, and ADT also resulted in
PCGEM1 relocalisation from the cytoplasm to the nucleus.
However, Prensner et al. subsequently reported that PCGEM1
and PRNCR1 were not implicated in CRPC or AR signalling [61].
They assessed the expression levels of PCGEM1 and PRNCR1 in 171
human prostatic tissues using RNA sequencing data aggregated
from four independent studies of PCa. They reported that PCGEM1
but not PRNCR1 was associated with PCa. They stated that neither
PCGEM1 nor PRNCR1 were associated with poor patient outcomes
after examining a cohort of 235 high-risk PCa patients with long-
term outcome data. They were also unable to observe PCGEM1 or
PRNCR1 interacting with the AR or acting as a component of AR
signalling.
This issue was further investigated by Parolia et al. who noted
that the published data on the relationship between the AR and
Fig. 1. lncRNAs that have been shown to interact with the Androgen Receptor (AR).
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PCGEM1/PRNCR1 had been derived from in vitro experiments, us-
ing androgen-sensitive LNCaP cells [62]. As the AR has been re-
ported to induce varied AR transcriptional programmes in patient
tumour tissue compared to PCa cell lines [94], they used Living
Tumour Laboratory (LTL) patient-derived xenograft PCa models
with the intention of more accuratelymirroring the pathogenesis of
PCa. They analysed RNA sequencing data from two distinct
androgen-dependent models and reported that PCGEM1 was
considerably expressed in PCa, while PRNCR1 showed scant
expression in keeping with the findings of Prensner et al. [61].
PCGEM1was reported to be implicated in early stage PCa but not in
metastatic PCa, was significantly downregulated in metastatic tu-
mours relative to primary tumours and significantly repressed in
patients exhibiting poor clinical outcomes [62]. They also observed
a significant decrease in PCGEM1 expression and reduced AR ac-
tivity post-castration, contradicting findings made by Yang et al.
[60]. However, in contrast to Prensner et al. [61], they found in vivo
stimulation of the AR led to upregulation of PCGEM1 [62]. AR
activation did not alter the subcellular localisation of PCGEM1, and
it was evenly distributed between the nucleus and the cytoplasm.
Two subsequent studies by Zhang et al. [63]and Ho et al. [63,64]
found that PCGEM1 was upregulated in response to ADT in vitro
which is supportive of the original conclusions by Yang et al. [60].
Zhang et al. [63] reported that suppression of PCGEM1 significantly
reduced tumour growth and tumour weight in castrated mice, and
also resulted in subcellular redistribution of PCGEM1 from the
cytoplasm to the nucleus. Ho et al. [64]also identified p54/nrb, a
ubiquitously expressed nuclear protein, as a positive regulator of
PCGEM1 levels.
Another mechanism of lncRNAs regulating the AR is through
interactions with miRNAs. PlncRNA-1 appears to protect the AR
from miRNA-mediated suppression [68] by acting as a sponge for
certain AR-targeting microRNAs such as miR-34c and miR-297.
HOTAIR was reported to be targeted by miR-34a [30] and
PCGEM1 by miR-145 [66].
3.1.2. Negative regulation of the AR
GAS5 negatively regulates the AR by binding to the DNA-binding
domain of the AR preventing it from binding to target DNA se-
quences [22].
3.1.3. LncRNAs regulated by the androgen receptor
AR activation is reported to upregulate lncRNAs PCAT18 and
SOCS-AS1 resulting in enhanced PCa cell proliferation, migration
and invasion [56,83]. In vitro analysis suggested that the AR indi-
rectly activates PCAT18 expression. Microarray data revealed 402
genes positively and significantly associated with PCAT18 expres-
sion. This expression signature was strongly associated with AR
activation. SOCS2-AS1 is induced by androgen and may modulate
AR activity by altering the epigenetic control for AR target genes.
AR activation is reported to repress the transcription of tumour
suppressors DRAIC and PCAT29 and also repress PCAT14, a lncRNA
associated with favourable clinical outcomes in PCa [18,54,56].
PCAT29 is also reported to be indirectly repressed by IL-6, a cyto-
kine which is elevated in prostate tumours [58]. IL-6 activates
STAT3 which induces miR-21 and this interaction leads to the
repression of PCAT29.
3.1.4. AR splice variants
MALAT-1 is reported to induce AR-V7 production in vitro and
may enhance splicing of AR-V7 through direct modulation of SF2
binding and activity [39].
Zhang et al. reported that after ADT, PCGEM1 relocated from the
cytoplasm to nuclear speckles where it interacted with U2AF65,
promoting its interactionwith AR pre-mRNA and promoting AR-V7
production [63]. PCGEM1 also interacted with hnRNPA1, a
repressor of AR-V7, causing a significant decrease in the ability of
hnRNPA1 to interact with AR pre-mRNA. As mentioned previously,
there are conflicting reports in the literature regarding PCGEM1
and some studies did not show subnuclear relocalisation of
PCGEM1 after ADT or promotion of AR-V7 production [61,62].
Fig. 2. lncRNA associated with EMT and Prostate Cancer.
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3.2. EMT
EMT is an important step in metastasis, during which non-
motile polarised epithelial cells convert into individual, motile
mesenchymal cells [95]. EMT has also been associated with resis-
tance to various anti-cancer therapies [96]. In PCa, numerous
lncRNAs are associated with the promotion of EMT (Fig. 2).
Many of these, such as CCAT2, LOC400891, LOC440040, PCA3
and LINC01296 have been associated with increased/decreased
expression of N-cadherin, vimentin, b-catenin, Twist, Snail,
claudin-3 and E-cadherin [14,31,35,36,45]. PlncRNA-1 induces EMT
through the TGF-b1 pathway [69]. ZEB1-AS1 promotes ZEB1
expression by binding and recruiting histone methyltransferase
MLL1 to the promoter region of ZEB1 [91]. ZEB1 is known to pro-
mote EMT [97,98]. LncRNA-ATB also upregulates ZEB1 as well as
modulating expression levels of E-cadherin, ZO-1, N-cadherin and
vimentin [33]. UCA1 promotes EMT through the targeting of miR-
204 [90]. MiR-204 negatively modulates Sirt1 expression so UCA1
overexpression results in increased Sirt1 expression. Upregulation
of Sirt1 is associated with the promotion of EMT.
4. Discussion
The study of lncRNAs has emerged as a burgeoning area of
cancer research and, accordingly, there has been a surge in publi-
cations in this area in recent years. LncRNAs appear to regulate key
functions in cancer cells including sustained proliferative signal-
ling, replicative immortality, invasion and metastasis, evasion of
growth suppressors, induction of angiogenesis and resistance to
apoptosis [12]. However, with over 100,000 lncRNAs identified to
date, the mechanisms of action of most lncRNAs remains unknown.
In this report, we have reviewed the literature and provided an
up to date summary of the lncRNAs reported to be involved in
prostate carcinogenesis. We have reviewed 34 specific lncRNAs and
found that lncRNAs in PCa exert their actions through various
mechanisms including, but not limited to, regulation of (i) AR
expression pathway, (ii) EMT, (ii) miRNAs and (iv) PI3K/AKT/mTOR
pathway. We have focused on lncRNAs involved in the regulation of
the AR expression pathway as sustained AR activity is known to be a
critical component in prostate carcinogenesis, even after ADT [99].
The clinical use of lncRNAs has, so far, been restricted to their
use as biomarkers. Their potential as therapeutic targets to halt
disease progression has yet to be realised. In addition, as in any
nascent research field, the number of large scale studies validating
original findings are small and there are conflicting findings in the
literature with regards to the role of some lncRNAs. Many of the
summaries provided in this article are based on single reports,
often involving predominantly or solely in vitro experiments.
Further large scale in vivo studies are required to validate many of
the findings mentioned in this article.
5. Conclusion
LncRNAs are involved in the regulation of key processes in
prostate carcinogenesis, particularly the AR expression pathway
and EMT pathway. However, the extent of the role that lncRNAs
play in prostate carcinogenesis has yet to be fully elucidated. This
lack of knowledge demands that we exercise caution when inter-
preting results, particularly when based on single studies. That
being said, the study of lncRNAs is currently an exciting area of
cancer research precisely because there is much that is unknown.
Unlocking the role of lncRNAs may provide crucial insights into the
pathogenesis of PCa and we hope that this knowledge can be
transferred into clinical benefits for patients through the use of
better biomarkers to detect disease progression, to identify patients
who will respond to targeted therapies and to act as targets for
future therapies that may halt the progression of this prevalent
disease.
A summary of known interactions/associations of various
lncRNAs (and miRNAs) discussed in the text that are linked to the
Androgen Receptor.
A summary of lncRNAs which have been linked to EMT in
prostate cancer, some of which have been directly linked to the AR,
and which have been discussed in more detail in the text.
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